Image Place holder

Jason B. Brayer, MD, PhD


Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

or call 1-888-MOFFITT
(1-888-663-3488)

Overview

Cancer Types Treated: Multiple Myeloma-Plasma Cell Tumor

My clinical interests include:• Treatment of plasma cell disorders including MGUS, multiple myeloma, and Waldenstrom’s Macroglobulinemia.• Participation or leadership in clinical trials investigating the development of immunotherapeutic approaches in multiple myeloma (including immunomodulatory agents, vaccine studies, and cellular-based adoptive immunotherapy)

Education & Training

Board Certification:

  • Hematology
  • Medical Oncology

Fellowship:

  • La Jolla Institute of Allergy & Immunology - Immunology
  • H. Lee Moffitt Cancer Center and Research Institute -
  • H. Lee Moffit Cancer Center and Research Institute - Hematology/Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of South Florida - MD
Participating Trials

CLINICAL TRIAL 18891
A Multinational Open-Label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients with Different Metastatic Tumor Types
Condition:
Intervention: NKR-2
Open

CLINICAL TRIAL 19378
A Phase 1 Study of SGN-CD48A in Patients with Relapsed or Refractory Multiple Myeloma
Condition:
Intervention: Not Applicable; SGN-CD48A
Open

CLINICAL TRIAL 18346
Evaluating the Safety and Biological Activity of a Dendritic Cell Survivin Vaccine in Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplantation
Condition:
Intervention: G-CSF; Prevnar13; Survivin-Dendritic Cell Vaccine
Open

CLINICAL TRIAL 17790
A Randomized Phase II Study of Autologous Stem Cell Transplantation with Tadalafil and Lenalidomide Maintenance with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma
Condition:
Intervention: Alkeran (Melphalan); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Marrow Infiltrating Lymphocytes (MILs); Melphalan; Tadalafil
Open

CLINICAL TRIAL 18950
A Phase I/Ib Study of Ipilimumab or Nivolumab in Patients with Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation
Condition:
Intervention: BMS-936558 (Nivolumab); Nivolumab
Open

CLINICAL TRIAL 19079
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination with Pomalidomide and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma
Condition:
Intervention: CC-4047 (Pomalidomide); Dexamethasone; Oprozomib; Pomalidomide
Open

CLINICAL TRIAL 19230
Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib,and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
Condition:
Intervention: Bortezomib; CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Lenalidomide (Revlimid); PS-341 (Bortezomib); Velcade (Bortezomib)
Open

CLINICAL TRIAL 19194
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
Condition:
Intervention: bb21217
Open

CLINICAL TRIAL 19331
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects with Relapsed/Refractory Multiple Myeloma
Condition:
Intervention: KITE-585; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19158
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Condition:
Intervention: Atezolizumab (Tecentriq)
Open

CLINICAL TRIAL 19197
A Randomized Parallel Phase 2 Study of Elotuzumab plus Lenalidomide (Elo/Rev) for the Treatment of Serologic Relapse/Progression while on Lenalidomide Maintenance for Multiple Myeloma
Condition:
Intervention: CC-5013 (Lenalidomide); Elotuzumab; Lenalidomide (Revlimid)
Open

If you believe you are eligible for one of these trials or studies, please call
1-888-MOFFITT (1-888-663-3488).

Publications

  • Rose AM, Brayer J. Connecting the dots: A case of myeloid sarcoma. Am J Med. 2018 May. Pubmedid: 29729239.
  • Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 2018 Apr. Pubmedid: 29703727.
  • Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017 Nov;7(11):e017075. Pubmedid: 29133316. Pmcid: PMC5695348.
  • Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jul;8(7):209-220. Pubmedid: 28694935. Pmcid: PMC5495505.
  • Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul;90(7):602-607. Pubmedid: 25802083. Pmcid: PMC4617516.
  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leuk Lymphoma. 2014 Nov;55(11):2660-2662. Pubmedid: 24528217.
  • Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother. 2014 Apr;37(3):187-191. Pubmedid: 24598453.
  • Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010 Jul;131(2):126-130. Pubmedid: 20346983. Pmcid: PMC2906450.
  • Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett. 2009 Aug;125(2):114-118. Pubmedid: 19555720. Pmcid: PMC2758552.
  • Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr;107(7):2871-2878. Pubmedid: 16339406. Pmcid: PMC1895389.
  • Ghansah T, Paraiso K, Highfill S, Desponts C, May S, McIntosh J, Wang J, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr W. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol. 2004 Dec;173(12):7324-7330. Pubmedid: 15585856.
  • Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004 Aug;64(16):5839-5849. Pubmedid: 15313928.
  • Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr W, TakedaK, Akira S, Schoenberger S, Yu H, Jove R, Sotomayor E. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003 Sep;19(3):425-436. Pubmedid: 14499117.
  • Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello I, Levitsky H, Sotomayor E. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003;63(24):9007-9015. Pubmedid: 14695219.